TABLE 1.
Characteristics of SPRINT participants in the ABPM ancillary study
| Intensive-treatment | Standard-treatment | ||
|---|---|---|---|
| Variable | N = 453 | N = 444 | p-value |
| Age (years, 27M) | 71.5 ± 9.3 | 71.5 ± 9.7 | 0.898 |
| Female sex | 132 (29.1) | 125 (28.2) | 0.801 |
| Race / Ethnicity | 0.502 | ||
| White | 300 (66.2) | 304 (68.5) | |
| Black | 127 (28.0) | 124 (27.9) | |
| Hispanic | 13 (2.9) | 8 (1.8) | |
| Other | 13 (2.9) | 8 (1.8) | |
| Body Mass Index (kg/m2, 24M) | 29.6 ± 5.7 | 29.4 ± 5.5 | 0.570 |
| Smoking status (24M) | 0.999 | ||
| Never smoker | 208 (46.0) | 204 (45.9) | |
| Former smoker | 203 (44.9) | 200 (45.0) | |
| Current smoker | 41 (9.1) | 40 (9.0) | |
| Alcohol use (Baseline) | 0.098 | ||
| Non-drinker | 171 (37.7) | 178 (40.1) | |
| Light drinker | 91 (20.1) | 89 (20.0) | |
| Moderate drinker | 117 (25.8) | 99 (22.3) | |
| Heavy drinker | 43 (9.5) | 60 (13.5) | |
| Unknown | 31 (6.8) | 18 (4.1) | |
| History of CVD (Baseline) | 94 (20.8) | 101 (22.7) | 0.520 |
| Experienced CVD event before ABPM study | 15 (3.3) | 14 (3.2) | 1.000 |
| eGFR (ml/min/1.73 m2, 24M) | 67.3 ± 20.2 | 73.4 ± 21.1 | <0.001 |
| Urine albumin/Cr (mg/g, 24M) | 7.9 (4.9 to 15.2) | 10.6 (6.1 to 28.4) | <0.001 |
| Total cholesterol (mg/dL, 24M) | 183.4 ± 39.9 | 178.4 ± 38.6 | 0.058 |
| HDL cholesterol (mg/dL, 24M) | 52.7 ± 17.2 | 53.5 ± 16.7 | 0.462 |
| Fasting HDL cholesterol only (mg/dL, 24M) | 52.8 ± 17.1 | 54 ± 16.7 | 0.336 |
| LDL cholesterol (mg/dL, 24M) | 107.9 ± 34.6 | 101.9 ± 32.6 | 0.008 |
| Fasting LDL cholesterol only (mg/dL, 24M) | 108.7 ± 34.5 | 102.6 ± 32.7 | 0.013 |
| Total triglycerides (mg/dL, 24M) | 100 (70.8 to 142) | 93 (63 to 145) | 0.193 |
| Fasting total triglycerides only (mg/dL, 24M) | 100 (71 to 141.5) | 89 (62 to 139) | 0.020 |
| 10-year Framingham CVD risk (%, Baseline) | 20.8 ± 11.1 | 20.8 ± 10.6 | 0.988 |
| Number of antihypertensive medications (27M) | 2.9 ± 1.2 | 1.8 ± 1.1 | <0.001 |
| Beta-blockers | 182 (40.2) | 125 (28.2) | <0.001 |
| Calcium channel blockers | 271 (59.8) | 145 (32.7) | <0.001 |
| ACE inhibitors | 163 (36.0) | 128 (28.9) | 0.028 |
| Angiotensin receptor blockers | 190 (41.9) | 141 (31.8) | 0.002 |
| Vasodilators | 26 (5.7) | 10 (2.3) | 0.013 |
| Alpha-blockers | 47 (10.4) | 33 (7.4) | 0.156 |
| Diuretics | 342 (75.5) | 188 (42.4) | <0.001 |
Values are n (%), mean ± standard deviation, or median (25th percentile to 75th percentile). (Baseline) Data collected at randomization visit. (24M) Data collected at 24 month annual visit. (27M) Data collected at 27M study visit. (eGFR) Estimated glomerular filtration rate based on MDRD study equation.